The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine, reported news agency ANI.
Earlier in mid-December, the company sought permission to conduct clinical trials for its intranasal booster dose.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
Bharat Biotech also manufactures the COVID-19 vaccine Covaxin, which was recently given emergency use authorisation for 12-18 year olds.
Appellate Tribunal NCLAT Rejects Plea Against Voltas, Says 'We Have Committed No Mistake'
'India's Export-Driven Businesses, Facing International Regulatory Shocks, Are Exposed To Risk Due To Climate Inaction Threatening Profits': BCG
'My Partner Is Half-Indian, One Of My Son's Middle Name Is Sekhar,' Reveals Elon Musk On Nikhil Kamath's Podcast | Video
Mumbai: 51-Year-Old Businesswoman Stripped & Assaulted At Gunpoint In Mahalaxmi Office
(With inputs from Agencies)
